Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-18-002067
Filing Date
2018-01-25
Accepted
2018-01-25 20:50:20
Documents
1
Period of Report
2018-01-25

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 6544
  Complete submission text file 0000899243-18-002067.txt   8647
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-38359 | Film No.: 18549697

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6400
OrbiMed Capital GP VI LLC (Reporting) CIK: 0001682115 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38359 | Film No.: 18549696

Mailing Address 501 BOYLSTON STREET SUITE 6102 BOSTON MA 02116
Business Address 501 BOYLSTON STREET SUITE 6102 BOSTON MA 02116 617-482-2333
resTORbio, Inc. (Issuer) CIK: 0001720580 (see all company filings)

EIN.: 813305277 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations